Multimodal Therapy of Upper Gastrointestinal Malignancies

Edited by
August 2021
272 pages
  • ISBN978-3-0365-0920-4 (Hardback)
  • ISBN978-3-0365-0921-1 (PDF)

This book is a reprint of the Special Issue Multimodal Therapy of Upper Gastrointestinal Malignancies that was published in

Biology & Life Sciences
Medicine & Pharmacology

Recent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole treatment for these tumors, multimodal therapies have meanwhile proven their efficacy. At present, pre- and postoperative chemotherapy and radiotherapy, targeted drug therapy, and stage-specific surgical approaches are all indispensable cornerstones of an individualized treatment for upper gastrointestinal malignancies. With such multimodal treatment, better outcomes comprising improved quality of life and prolonged survival have been achieved for patients. However, for many tumor entities and stages, the ideal combination and sequence of treatments is still being evaluated in clinical trials. Moreover, the value of novel approaches such as immunotherapy or robotic surgery remains a matter of research. In this Special Issue of Cancers, up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of upper gastrointestinal malignancies have been published.

  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
gastric cancer; gastrectomy; complications; outcome; survival; gastric cancer; lymph node ratio; neoadjuvant chemotherapy; gastric cancer; conversion surgery; cancer dormancy; nuclear receptor NR2F1; clinical pathways; gastric surgery; oncological gastrectomy; quality of care; outcomes; standardization; adjuvant therapy; gastrointestinal tract; genetic diagnosis; radiosensitivity; gastric cancer; gastrectomy; complications; mortality; failure to rescue; immunotherapy; genetics; gastric cancer; esophageal cancer; multidisciplinary; gastric/gastroesophageal cancer; perioperative chemotherapy; overall survival; relapse-free survival; skeletal muscle index; esophagectomy; nutritional status; sarcopenia; esophagectomy; esophageal anastomosis; minimally invasive surgery; induction chemotherapy; chemo-radiotherapy; neoadjuvant treatment; esophageal cancer; esophageal squamous cell carcinoma; multimodal treatment; neoadjuvant chemotherapy; neoadjuvant chemoradiotherapy; definitive chemoradiotherapy; gastric/gastroesophageal cancer; perioperative chemotherapy; Lauren histotype; esophageal cancer; gastric cancer; gastrointestinal stromal tumor; neuroendocrine tumor; MALT lymphoma; mucosal resection; submucosal dissection; gastrointestinal stromal tumor; GIST; stomach; neoadjuvant therapy; imatinib; organ preservation; squamous cell esophageal cancer; gastro-esophageal reflux disease; Barrett’s esophagus; early adenocarcinoma of esophagus; endoscopic submucosal dissection; endoscopic mucosal resection; n/a